Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Paul A. Cohen; Aime Powell; Steffen Böhm; C. Blake Gilks; Colin J.R. Stewart; Tarek M. Meniawy; Max Bulsara; Stefanie Avril; Eleanor C. Brockbank; Tjalling Bosse; Gustavo Rubino De Azevedo Focchi; Raji Ganesan; Rosalind M. Glasspool; Brooke E. Howitt; Hyun-Soo Kim; Jung-Yun Lee; N. D. Le; Michelle Lockley; Ranjit Manchanda; Trupti Mandalia; W. Glenn Mccluggage; Iain Mcneish; D. Midha; Radhika Srinivasan; Yun Yi Tan; Rachael Van Der Griend; Mayu Yunokawa; Gian Franco Zannoni; Simi Aggarwal; Holger Bronger; Elizabeth B. Brown; Martin Buck; Syed A. Bukhari; Edwina Coghlan; Nichola Cope; Michelle Samora De Almeida; Cornelius D. De Kroon; Andrew Dean; Michael-John Devlin; Helena M. Ditzel; E. Drecoll; Anna Fagotti; Asma Faruqi; L. Feeney; Kavita Gupta; Ian Harley; Frediano Inzani; Arjun R. Jeyarajah; M.H. Eleanor Koay; Judith R. Kroep; Yee Leung; Alice R. Loft; Daniel Magee; S. Mckenna; D. Millan; Joanne Millar; R. Miller; Ganendra R. Mohan; Sohail Mughal; Sergio Mancini Nicolau; J. Nevin; Abigail S. Oakley; Mary Quigley; Michelle Quigley; Bhavana Rai; Barbara Praitano; Arvind Rajwanshi; Stuart G. Salfinger; Giovanni Scambia; Kate Scatchard; Barbara Schmalfeldt; Bryony Simcock; P. Singh; Kyle C. Strickland; Vainta Suri; Sheeba Syed; P. Sykes; Adeline Tan; J. Tan; E. Thompson; Anna V. Tinker; Georgia Trevisan; Gian Rolando Trevisani; Maria Gabriela Baumgarten Kuster Uyeda; Michelle M. Vaughan; W. Weichert; Anthony Williams; S. Williams; Pier Carlo Zorzato; Naveena Singh; Manprietkaur Singh

doi:10.1016/j.ygyno.2019.04.679

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Paul A. Cohen, Aime Powell, Steffen Böhm, C. Blake Gilks, Colin J.R. Stewart, Tarek M. Meniawy, Max Bulsara, Stefanie Avril, Eleanor C. Brockbank, Tjalling Bosse, Gustavo Rubino De Azevedo Focchi, Raji Ganesan, Rosalind M. Glasspool, Brooke E. Howitt, Hyun-Soo Kim, Jung-Yun Lee, N. D. Le, Michelle Lockley, Ranjit Manchanda, Trupti MandaliaW. Glenn Mccluggage, Iain Mcneish, D. Midha, Radhika Srinivasan, Yun Yi Tan, Rachael Van Der Griend, Mayu Yunokawa, Gian Franco Zannoni, Simi Aggarwal, Holger Bronger, Elizabeth B. Brown, Martin Buck, Syed A. Bukhari, Edwina Coghlan, Nichola Cope, Michelle Samora De Almeida, Cornelius D. De Kroon, Andrew Dean, Michael-John Devlin, Helena M. Ditzel, E. Drecoll, Anna Fagotti, Asma Faruqi, L. Feeney, Kavita Gupta, Ian Harley, Frediano Inzani, Arjun R. Jeyarajah, M.H. Eleanor Koay, Judith R. Kroep, Yee Leung, Alice R. Loft, Daniel Magee, S. Mckenna, D. Millan, Joanne Millar, R. Miller, Ganendra R. Mohan, Sohail Mughal, Sergio Mancini Nicolau, J. Nevin, Abigail S. Oakley, Mary Quigley, Michelle Quigley, Bhavana Rai, Barbara Praitano, Arvind Rajwanshi, Stuart G. Salfinger, Giovanni Scambia, Kate Scatchard, Barbara Schmalfeldt, Bryony Simcock, P. Singh, Kyle C. Strickland, Vainta Suri, Sheeba Syed, P. Sykes, Adeline Tan, J. Tan, E. Thompson, Anna V. Tinker, Georgia Trevisan, Gian Rolando Trevisani, Maria Gabriela Baumgarten Kuster Uyeda, Michelle M. Vaughan, W. Weichert, Anthony Williams, S. Williams, Pier Carlo Zorzato, Naveena Singh, Manprietkaur Singh

Risultato della ricerca: Contributo in rivista › Articolo in rivista

24 Citazioni (Scopus)

Abstract

Objective: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. Methods: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS). Results: 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5–65) and 28 months (IQR 7–92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45–0·66; P < 0·001) and 0·65 (95% CI 0·50–0·85, P = 0·002) respectively; no heterogeneity was identified (PFS: Q = 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027). Conclusions: CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design.

Lingua originale	English
pagine (da-a)	441-448
Numero di pagine	8
Rivista	Gynecologic Oncology
Volume	154
DOI	https://doi.org/10.1016/j.ygyno.2019.04.679
Stato di pubblicazione	Pubblicato - 2019

Keywords

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Carboplatin
Chemotherapy response score
Disease-Free Survival
Fallopian Tube Neoplasms
Female
High-grade serous tubo-ovarian cancer
Humans
Neoadjuvant Therapy
Neoadjuvant chemotherapy
Neoplasms, Cystic, Mucinous, and Serous
Ovarian Neoplasms
Prognosis
Treatment Outcome

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.ygyno.2019.04.679

Altri file e collegamenti

Open Access link a IRIS PubliCatt

Cita questo

Cohen, P. A., Powell, A., Böhm, S., Gilks, C. B., Stewart, C. J. R., Meniawy, T. M., Bulsara, M., Avril, S., Brockbank, E. C., Bosse, T., De Azevedo Focchi, G. R., Ganesan, R., Glasspool, R. M., Howitt, B. E., Kim, H.-S., Lee, J.-Y., Le, N. D., Lockley, M., Manchanda, R., ... Singh, M. (2019). Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 154, 441-448. https://doi.org/10.1016/j.ygyno.2019.04.679

@article{5b4f3514c97a4c11b8fa430e038a91ba,

title = "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data",

abstract = "Objective: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. Methods: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS). Results: 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5–65) and 28 months (IQR 7–92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45–0·66; P < 0·001) and 0·65 (95% CI 0·50–0·85, P = 0·002) respectively; no heterogeneity was identified (PFS: Q = 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027). Conclusions: CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design.",

keywords = "Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carboplatin, Chemotherapy response score, Disease-Free Survival, Fallopian Tube Neoplasms, Female, High-grade serous tubo-ovarian cancer, Humans, Neoadjuvant Therapy, Neoadjuvant chemotherapy, Neoplasms, Cystic, Mucinous, and Serous, Ovarian Neoplasms, Prognosis, Treatment Outcome, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carboplatin, Chemotherapy response score, Disease-Free Survival, Fallopian Tube Neoplasms, Female, High-grade serous tubo-ovarian cancer, Humans, Neoadjuvant Therapy, Neoadjuvant chemotherapy, Neoplasms, Cystic, Mucinous, and Serous, Ovarian Neoplasms, Prognosis, Treatment Outcome",

author = "Cohen, {Paul A.} and Aime Powell and Steffen B{\"o}hm and Gilks, {C. Blake} and Stewart, {Colin J.R.} and Meniawy, {Tarek M.} and Max Bulsara and Stefanie Avril and Brockbank, {Eleanor C.} and Tjalling Bosse and {De Azevedo Focchi}, {Gustavo Rubino} and Raji Ganesan and Glasspool, {Rosalind M.} and Howitt, {Brooke E.} and Hyun-Soo Kim and Jung-Yun Lee and Le, {N. D.} and Michelle Lockley and Ranjit Manchanda and Trupti Mandalia and Mccluggage, {W. Glenn} and Iain Mcneish and D. Midha and Radhika Srinivasan and Tan, {Yun Yi} and {Van Der Griend}, Rachael and Mayu Yunokawa and Zannoni, {Gian Franco} and Simi Aggarwal and Holger Bronger and Brown, {Elizabeth B.} and Martin Buck and Bukhari, {Syed A.} and Edwina Coghlan and Nichola Cope and {De Almeida}, {Michelle Samora} and {De Kroon}, {Cornelius D.} and Andrew Dean and Michael-John Devlin and Ditzel, {Helena M.} and E. Drecoll and Anna Fagotti and Asma Faruqi and L. Feeney and Kavita Gupta and Ian Harley and Frediano Inzani and Jeyarajah, {Arjun R.} and Koay, {M.H. Eleanor} and Kroep, {Judith R.} and Yee Leung and Loft, {Alice R.} and Daniel Magee and S. Mckenna and D. Millan and Joanne Millar and R. Miller and Mohan, {Ganendra R.} and Sohail Mughal and Nicolau, {Sergio Mancini} and J. Nevin and Oakley, {Abigail S.} and Mary Quigley and Michelle Quigley and Bhavana Rai and Barbara Praitano and Arvind Rajwanshi and Salfinger, {Stuart G.} and Giovanni Scambia and Kate Scatchard and Barbara Schmalfeldt and Bryony Simcock and P. Singh and Strickland, {Kyle C.} and Vainta Suri and Sheeba Syed and P. Sykes and Adeline Tan and J. Tan and E. Thompson and Tinker, {Anna V.} and Georgia Trevisan and Trevisani, {Gian Rolando} and Uyeda, {Maria Gabriela Baumgarten Kuster} and Vaughan, {Michelle M.} and W. Weichert and Anthony Williams and S. Williams and Zorzato, {Pier Carlo} and Naveena Singh and Manprietkaur Singh",

year = "2019",

doi = "10.1016/j.ygyno.2019.04.679",

language = "English",

volume = "154",

pages = "441--448",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

Cohen, PA, Powell, A, Böhm, S, Gilks, CB, Stewart, CJR, Meniawy, TM, Bulsara, M, Avril, S, Brockbank, EC, Bosse, T, De Azevedo Focchi, GR, Ganesan, R, Glasspool, RM, Howitt, BE, Kim, H-S, Lee, J-Y, Le, ND, Lockley, M, Manchanda, R, Mandalia, T, Mccluggage, WG, Mcneish, I, Midha, D, Srinivasan, R, Tan, YY, Van Der Griend, R, Yunokawa, M, Zannoni, GF, Aggarwal, S, Bronger, H, Brown, EB, Buck, M, Bukhari, SA, Coghlan, E, Cope, N, De Almeida, MS, De Kroon, CD, Dean, A, Devlin, M-J, Ditzel, HM, Drecoll, E, Fagotti, A, Faruqi, A, Feeney, L, Gupta, K, Harley, I, Inzani, F, Jeyarajah, AR, Koay, MHE, Kroep, JR, Leung, Y, Loft, AR, Magee, D, Mckenna, S, Millan, D, Millar, J, Miller, R, Mohan, GR, Mughal, S, Nicolau, SM, Nevin, J, Oakley, AS, Quigley, M, Quigley, M, Rai, B, Praitano, B, Rajwanshi, A, Salfinger, SG, Scambia, G, Scatchard, K, Schmalfeldt, B, Simcock, B, Singh, P, Strickland, KC, Suri, V, Syed, S, Sykes, P, Tan, A, Tan, J, Thompson, E, Tinker, AV, Trevisan, G, Trevisani, GR, Uyeda, MGBK, Vaughan, MM, Weichert, W, Williams, A, Williams, S, Zorzato, PC, Singh, N & Singh, M 2019, 'Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data', Gynecologic Oncology, vol. 154, pagg. 441-448. https://doi.org/10.1016/j.ygyno.2019.04.679

TY - JOUR

T1 - Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

AU - Cohen, Paul A.

AU - Powell, Aime

AU - Böhm, Steffen

AU - Gilks, C. Blake

AU - Stewart, Colin J.R.

AU - Meniawy, Tarek M.

AU - Bulsara, Max

AU - Avril, Stefanie

AU - Brockbank, Eleanor C.

AU - Bosse, Tjalling

AU - De Azevedo Focchi, Gustavo Rubino

AU - Ganesan, Raji

AU - Glasspool, Rosalind M.

AU - Howitt, Brooke E.

AU - Kim, Hyun-Soo

AU - Lee, Jung-Yun

AU - Le, N. D.

AU - Lockley, Michelle

AU - Manchanda, Ranjit

AU - Mandalia, Trupti

AU - Mccluggage, W. Glenn

AU - Mcneish, Iain

AU - Midha, D.

AU - Srinivasan, Radhika

AU - Tan, Yun Yi

AU - Van Der Griend, Rachael

AU - Yunokawa, Mayu

AU - Zannoni, Gian Franco

AU - Aggarwal, Simi

AU - Bronger, Holger

AU - Brown, Elizabeth B.

AU - Buck, Martin

AU - Bukhari, Syed A.

AU - Coghlan, Edwina

AU - Cope, Nichola

AU - De Almeida, Michelle Samora

AU - De Kroon, Cornelius D.

AU - Dean, Andrew

AU - Devlin, Michael-John

AU - Ditzel, Helena M.

AU - Drecoll, E.

AU - Fagotti, Anna

AU - Faruqi, Asma

AU - Feeney, L.

AU - Gupta, Kavita

AU - Harley, Ian

AU - Inzani, Frediano

AU - Jeyarajah, Arjun R.

AU - Koay, M.H. Eleanor

AU - Kroep, Judith R.

AU - Leung, Yee

AU - Loft, Alice R.

AU - Magee, Daniel

AU - Mckenna, S.

AU - Millan, D.

AU - Millar, Joanne

AU - Miller, R.

AU - Mohan, Ganendra R.

AU - Mughal, Sohail

AU - Nicolau, Sergio Mancini

AU - Nevin, J.

AU - Oakley, Abigail S.

AU - Quigley, Mary

AU - Quigley, Michelle

AU - Rai, Bhavana

AU - Praitano, Barbara

AU - Rajwanshi, Arvind

AU - Salfinger, Stuart G.

AU - Scambia, Giovanni

AU - Scatchard, Kate

AU - Schmalfeldt, Barbara

AU - Simcock, Bryony

AU - Singh, P.

AU - Strickland, Kyle C.

AU - Suri, Vainta

AU - Syed, Sheeba

AU - Sykes, P.

AU - Tan, Adeline

AU - Tan, J.

AU - Thompson, E.

AU - Tinker, Anna V.

AU - Trevisan, Georgia

AU - Trevisani, Gian Rolando

AU - Uyeda, Maria Gabriela Baumgarten Kuster

AU - Vaughan, Michelle M.

AU - Weichert, W.

AU - Williams, Anthony

AU - Williams, S.

AU - Zorzato, Pier Carlo

AU - Singh, Naveena

AU - Singh, Manprietkaur

PY - 2019

Y1 - 2019

N2 - Objective: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. Methods: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS). Results: 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5–65) and 28 months (IQR 7–92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45–0·66; P < 0·001) and 0·65 (95% CI 0·50–0·85, P = 0·002) respectively; no heterogeneity was identified (PFS: Q = 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027). Conclusions: CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design.

AB - Objective: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. Methods: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS). Results: 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5–65) and 28 months (IQR 7–92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45–0·66; P < 0·001) and 0·65 (95% CI 0·50–0·85, P = 0·002) respectively; no heterogeneity was identified (PFS: Q = 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027). Conclusions: CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design.

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Biomarkers, Tumor

KW - Carboplatin

KW - Chemotherapy response score

KW - Disease-Free Survival

KW - Fallopian Tube Neoplasms

KW - Female

KW - High-grade serous tubo-ovarian cancer

KW - Humans

KW - Neoadjuvant Therapy

KW - Neoadjuvant chemotherapy

KW - Neoplasms, Cystic, Mucinous, and Serous

KW - Ovarian Neoplasms

KW - Prognosis

KW - Treatment Outcome

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Biomarkers, Tumor

KW - Carboplatin

KW - Chemotherapy response score

KW - Disease-Free Survival

KW - Fallopian Tube Neoplasms

KW - Female

KW - High-grade serous tubo-ovarian cancer

KW - Humans

KW - Neoadjuvant Therapy

KW - Neoadjuvant chemotherapy

KW - Neoplasms, Cystic, Mucinous, and Serous

KW - Ovarian Neoplasms

KW - Prognosis

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/150768

U2 - 10.1016/j.ygyno.2019.04.679

DO - 10.1016/j.ygyno.2019.04.679

M3 - Article

SN - 0090-8258

VL - 154

SP - 441

EP - 448

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo